Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III

Current Opinion in Neurology

Volumn 12, Issue 2, 1999, Pages 167-176

  Krivit, William ^a   Peters, Charles ^a   Shapiro, Elsa G ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOLEUKODYSTROPHY; ASPARTYLGLYCOSAMINURIA; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASE; DISORDERS OF PEROXISOMAL FUNCTIONS; ENZYME ACTIVITY; FUCOSIDOSIS; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIFESPAN; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MAROTEAUX LAMY SYNDROME; METACHROMATIC LEUKODYSTROPHY; MUCOPOLYSACCHARIDOSIS TYPE 7; REVIEW; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; METABOLISM, INBORN ERRORS; TREATMENT OUTCOME;

EID: 0032941197     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199904000-00007     Document Type: Review

References (81)

1. Krivit W. Correction of inborn errors of metabolism treated by bone marrow transplantation. In: Basic biology of new developments in biotechnology. Hollaender A, Laskin A, Rogers P (editors). New York: Plenum Publishing Corporation; 1983. pp. 63-76.
2. Whitley CB, Ramsay NKC, Kersey JH, Krivit W. Bone marrow transplantation in Hurler syndrome: assessment of metabolic correction. In: Bone marrow transplantation for treatment of lysosomal storage diseases. Vol. 22, No. 1. Krivit W, Paul NP (editors). New York: March of Dimes; 1986. pp. 7-24.
3. Krivit W, Shapiro E, Hoogerbrugge RM, Moser H. State of the art review bone marrow transplantation treatment for storage diseases. Bone Marrow Transplant 1992; 10:87-96.
4. Krivit W, Sung JH, Lockrnan LA, Shapiro EG. Bone marrow transplantation for treatment of lysosomal and peroxisomal storage diseases: focus on central nervous system reconstitution. In: Principles of clinical immunology. Vol. 2. Rich RR, Fleisher TA, Schwartz BD, Shearer WT, Strober W (editors). St. Louis: Mosby; 1995. pp. 1852-1864.
5. Krivit W, Shapiro EG, Lockman LA, Balthazor M, Wagner J, Peters C, et al. Bone marrow transplantation treatment for globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, and Hurler syndrome. In: Handbook of clinical neurology. Vol. 66, revised Series 22. Moser H, Vinken PJ, Bruyn GW (editors). Amsterdam: Elsevier; 1996. pp. 87-106.
6. Krivit W, Shapiro EG. Bone marrow transplantation for storage diseases. In: Treatment of genetic diseases. Desnick RJ (editor). Churchill-Livingstone: New York; 1991. pp. 203-221.
7. Krivit W, Whitley CB. Bone marrow transplantation in genetic disease [editorial]. N Engl J Med 1987; 310:1085-1087.
8. Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995; 4:385-392.
9. Unger E, Sung J, Manivel J, Chenggis M, Blazar B, Krivit W. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol 1993; 52:460-470.
10. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 1997; 94:4080-4085. The astrocytes are demonstrated to be derived from cells cultured from marrow. Several methods of identification were used.
11. Azizi SA, Stokes D, Augelli BJ, Digirolamo C, Prockop DJ. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino mice-similarities to astrocyte grafts. Proc Natl Acad Sci U S A 1998; 95:3908-3913. Mesenchymal stem cells cultured from human bone marrow were injected into the brains of albino mice. The graft from human rnesenchymal stem cells was established and cells were transformed into astrocytes as marrow cells grew outward from the site of injection.
12. Peters C, Krivit W. Microglia: the effector cell of the CNS following bone marrow transplantation. In: Correction of genetic diseases by transplantation IV. Ringden O, Hobbs JR, Steward CG (editors). Middlesex: Westminster Printing Press, The COGENT Trust IV; 1997. pp. 12-23. The background information and experimental data of rationale indicative of microglia derivation from donor marrow cells are presented.
13. Suzuki K, Tanike M. Murine model of genetic demyelinating disease: the twitcher mouse. Microsc Res Tech 1995; 32:204-214.
14. Shapiro EG, Lockman L, Kennedy W, Zimmerman D, Kolodny E, Raghavan S, et al. Bone marrow transplantation as treatment for globoid cell leukodystrophy. In: Treatment of genetic disease. Desnick RJ (editor). New York: Churchill-Livingstone; 1991. pp. 221-236.
15. Kolodny EH, Raghavan S, Krivit W. Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci 1991; 13:232-239.
16. DeGasperi R, Gama-Sosa MA, Sartorato EL, Battistini S, MacFarlane H, Gusella JF, et al. Molecular heterogeneity of late-onset forms of globoid cell leukodystrophy. Am J Hum Genet 1996; 59:1233-1242.
17. Chen YQ, Rafi MA, de Gala G, Wenger DA. Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum Mol Gen 1993; 2:1841-1845.
18. Ohno M, Komiyama A, Martin PM, Suzuki K. Proliferation of microglia/macrophages in the demyelinating CNS and PNS of twitcher mouse. Brain Res 1993; 602:268-274.
19. Krivit W, Shapiro EG, Peters C, Wagner JE, Cornu G, Kurtzberg J, et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 1998; 338:1119-1126. Globoid cell leukodystrophy patients responded excellently to the hematopoietic stem cell transplantation. Both late-onset and early-onset diseases responded equally well.
20. Bambach BJ, Moser HW, Blakemore K, Carson VL, Griffin CA, Noga SJ, et al. Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy. Bone Marrow Transplant 1997; 19:399-402.
21. Loes DJ, Peters C, Krivit W. Globoid cell leukodystrophy: distinguishing early onset from late onset disease using a brain MRI scoring method. Am J Neuro Radiol 1999; 20:316-323.
22. Shapiro EG, Lockman L, Krivit W. Recommendations for bone marrow transplant in late onset Krabbe disease (globoid cell leukodystrophy). In: Correction of genetic diseases by transplantation. II Hobbs JR (editor). Middlesex: Westminster Printing Press, The COGENT Trust; 1992. pp. 73-78.
23. Peters C, Krivit W. Hematopoietic stem cell transplantation for inborn errors of metabolism and prospects for gene therapy. J Gene Med (in press).
24. Krivit W, Lipton ME, Lockman LA, Tsai M, Dyck PJ, Smith S, et al. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am J Med Sci 1987; 294:80-85.
25. Lipton M, Lockman LD, Ramsay NKC, Kersey J, Jacobson R, Krivit W. Bone marrow transplantation in metachromatic loeukodystrophy. In: Bone marrow transplantation for treatment of lysosomal storage diseases, vol. 22. Krivit W, Paul NP (editors). New York: March of Dimes; 1986. pp. 57-68.
26. Shapiro EG, Lockman LA, Knopman D, Krivit W. Characteristics of the dementia in late-onset metachromatic leukodystrophy. Neurology 1992; 44:662-665.
27. Krivit W, Shapiro EG, Lockman LA, Kennedy W, Dhuna A, Ringden O, et al. Recommendations for treatment of MLD by BMT based on a review of seven patients who have been engrafted for at least a year: In: Correction of genetic diseases by transplation II. Hobbs JR (editor). London: Westminster Medical School Press; 1992. pp. 57-72.
28. Dhuna A, Toro C, Torres F, Kennedy WR, Krivit W. Longitudinal neurophysiological studies n a patient with MLD following BMT. Arch Neurol 1992; 49:1088-1092.
29. Krivit W, Shapiro E, Kennedy W, Lipton M, Lockman L, Smith S, et al. Effective treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N Eng J Med 1990; 3321:28-32.
30. Shapiro E, Lipton ME, Krivit W. White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant. J Clin Exp Neuropsychiatry 1992; 14:610-624.
31. Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromaticleukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis 1995; 18:398-412.
32. Shapiro E, Lockman L, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18:413-429.
33. Krivit W, Lockman LA, Shapiro EG. Metachromatic leukodystrophy. In: III. Steward CG, Hobbs JR (editors). London: Westminster Medical School Press; 1995. pp. 41-47
34. Kapaun P, Dittman RW, Granitzny B, Eickoff W, Walbrand H, Zander A, et al. Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantion. J Child Neurol 1999; 14: Presymptomatic patients with metachromatic leukodystrophy were treated with bone marrow transplantation. The details of transplantation and long-term results are presented.
35. Kidd D, Nelson J, Jones F. Long-term stablization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch Neurology 1998; 55:98-99.
36. Stillman AE, Krivit W, Shapiro EG, Lockman LA, Latchaw RE. Serial MR after bone marrow transplantation in two patients with metachromatic leukodystrophy: Am J Neurol Radiol 1994; 15:1929-1932.
37. Peters C, Waye J, Vellodi A, Fensom A, Sulzbacher S, Scott R, et al. Hematopoietic stem cell transplantation for metachromatic leukodystrophy prior to onset of clinical signs and symptoms. In: Cgorrection of genetic diseases by transplantation IV. Ringden O, Hobbs JR, Steward CG (editors). London: COGENT IV; Westminster: Middlesex Printing Press; 1997. pp. 34-48.
38. Krivit W, Shapiro E, Lockman L, Torres F, Stillman A, Moser A, Moser H. Recommendations for treatment of childhood cerebral form of adrenoleukodystrophy. In: Correction of genetic diseases by transplantation II. Hobbs JR (editor). London: Westminster Medical School Press; 1992. pp. 38-49.
39. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankfroff J, et al. Adrenoleukodystrophy: phenotypic variability: implications for therapy. J Inherit Metab Dis 1992; 15:645-664.
40. Loes DJ, Hite SW, Moser H, Stillman AE, Shapiro E, Lockman L, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. Am J Neurol Radiol 1994; 15:1761-1766.
41. Loes DJ, Stillman AE, Hite S, Shapiro E, Lockman L, Latchaw RE, et al. Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. Am J Neurol Radiol 1994; 15:1767-1771.
42. Phillips JP, Lockman LA, Shapiro EG, Blazar BR, Loes DJ, Moser HW, Krivit W. CSF findings in adrenoleukodystrophy: correlation between measures of cytokines, IgG production and disease severity. Ped Neurol 1994; 10:289-294.
43. Krivit W, Lockman LA, Shapiro EG. Childhood onset of adrenoleukodystrophy (COCALD): Effective treatment by bone marrow transplantation. In: Correction of genetic diseases by transplantation III. Steward CG, Hobbs JR (editors). COGENT IV. London: Westminster Medical School Press; 1995. pp. 48-56.
44. Rajanayagam V, Shapiro EG, Krivit W, Stillman AE. Proton MR spectroscopy of childhood adrenoleukodsytrophy. Am J Neurol Radiol 1996; 17:1013-1024.
45. Rajanayagam V, Balthazor M, Shapiro EG, Krivit W, Lockman L, Stillman AE. Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy. Am J Neurol Radiol 1997; 18:1909-1914. The use of proton magnetic resonance spectroscopy compared with neuropsychologic testing is presented. Magnetic resonance spectroscopy appears to be one of the best methods for detecting early onset of disease in adrenoleukodystrophy.
46. Shapiro E, Lockman LA, Balthazor M, Loes D, Rajanayagam V, Ziegler R, et al. Neuropsychological and neurological function and quality-of-life before and after bone marrow transplantation for adrenoleukodystrophy. In: Correction of genetic diseases by transplantation IV. Ringden O, Hobbs JR, Steward CG (editors). London: COGENT IV; Middlesex: Westminster Printing Press; 1997. pp. 52-61. A detailed analysis of adrenoleukodystrophy patients treated early during the course of their disease is presented. These patients were observed for 5-9 years after bone marrow transplantation. Neuropsychologic and MRI data indicate stability and improvement during this periods.
47. Kelly J. Bone marrow transplant can after the course of adrenoleukodystrophy: review of presentation by Shapiro at 26th Annual Meeting of the Child Neurology Society 1998; Neurology Reviews 12.
48. Antoku Y, Koike Ï, Ohtsuka Y. Adrenoleukodystrophy: a correlation between saturate very long chain fatty acids in mononuclear cells and phenotype. Ann Neurol 1991; 30:101-103.
49. Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNF α. J Neuroimmunol 1997; 76:70-74.
50. Prence EM, Natowicz MR. Diagnosis of alpha-mannosidosis by measuring alpha-mannosidase in plasma. Clin Chem. 1992; 38:501-503.
51. Wall DA, Grange DK, Goulding P, Daines M, Luisiri A, Kotagul S, et al. Bone marrow transplantation for the treatment of α-mannosidosis J Pediatr 1998; 133:282-285. This is the first clinical case of mannosidosis in which clinically positive effects were obtained. The skeletal system and neuropsychologic behavior improved after engraftment.
52. Walkley SU, Thrall MA, Dobrenis K, Huang M, March P, Siegel D, et al. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc Natl Acad Sci U S A 1994; 91:2970-2974.
53. Dobrennis K, Finamore PS, Masui R, Walkley SU. Mechanisms underlying successful treatment of neuronal storage disease [abstract 034]. 7th International Congress of Inborn Errors of Metabolism, Vienna, Austria, May, 1992.
54. Taylor RM, Farrow BRH, Stewart GJ. Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs. Am J Med Genet 1992; 42:628-632.
55. Vellodi A, Cragg H, Winchester B, Young E, Young J, Downie CJ, et al. Case report of allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant 1995; 15:153-158.
56. Autti T, Santavouri R, Raininko R, Renlund M, Lindahl E, Rapola J, et al. Bone marrow transplantation in aspartylglucosaminuria (AGU):MRI of the brain suggests normalizing myelination. In: Correction of genetic diseases by transplantation. London: COGENT IV; Middlesex: Westminster Printing Press; 1997. The barest details are given relative to positive effects of bone marrow transplantation in aspartylglucosaminuria patients. The data appear to be substantial, however, and the improvement in MRI appears to be real.
57. Whitley C, Krivit W, Ramsay N, Kersey J, Chang P, Latchaw K, Hopwood J. Mutation analysis and clinical outcome of patients with Hurler syndrome (mucopolysaccharidosis type 1-H) undergoing bone marrow transplantation [abstract]. Am J Hum Genet 1993; 53:101.
58. Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998; 9:250-253. The neuropsychological development after bone marrrow transplantation in Hurler's syndrome is addressed in some detail in this editorial.
59. Peters C, Shapiro EG, Krivit W. Hurler syndrome: past, present, and future. J Pediatrics 1998; 13:7-9.
60. Krivit W, Henslee-Downey J, Klemperer M, Cowan M, Peters C, Sanders J, et al. Survival of Hurler disease following bone marrow transplantation in 84 patients. Bone Marrow Transplant 1995; 15 (Suppl 1):182-185.
61. Krivit W, Shapiro EG, Balthazor M, Lockman LA, Summers CG, House JH, Ogilivie J. Hurler syndrome: outcomes and planning following bone marrow transplantation. In: Correction of genetic diseases by transplantation III. Steward CG, Hobbs JR (editors). London: Westminster Medical School Press; 1995. pp. 25-40.
62. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, et al. Outcome of unrelated donor bone marrow transplantation in forty children with Hurler syndrome. Blood 1996; 87:4894-4902.
63. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, et al. Hurler Syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children with Hurler syndrome. Blood 1998; 91:2601-2608. The results of bone marrow transplantation from human leukocyte antigen identical and related donors in Hurler's syndrome are presented. The data indicate that higher engraftment provides better neuropsychological score.
64. Krivit W, Pierpont ME, Ayaz K, Tsai M, Ramsay NKC, Kersey JH, et al. Bone marrow transplantation in Maroteaux-Lamy syndrome: biochemical and clinical studies 24 months post transplant. N Engl J Med 1984; 311:1606-1611.
65. Krivit W. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): treatment by allogeneic BMT in 6 patients and potential for autotransplantation bone marrow gene insertion. Int Pediatr 1992; 7:47-52.
66. Hite SH, Krivit W, Haines SJ, Whitley CB. Syringomyelia in mucopolyscaccharidosis type VI (Maroteaux-Lamy syndrome): imaging findings following bone marrow transplantation. Pediatr Radiol 1997; 27:736-738.
67. Alvaro F, Toogood I, Fletcher JM, Clement P, Rareling T, To B, et al. Case report: allogeneic CD34 selected peripheral stem cell transplant for Maroteaux-Lamy syndrome (mucopolysaccharidosis type Vi): rapid haemopoietic and biochemical reconstitution: Bone Marrow Transplant 1998; 21:419-421. Good data is reported on a Maroteaux-Lamy syndrome patient 2 years after transplantation.
68. Yamada YK, Kato K, Sukegawa K. Bone marrow transplantation 1998; 21:629-634
69. Snyder EY, Taylor RM, Wolfe JM. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374:367-370.
70. Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of glucuronidase. Nature Med 1997; 3:771-774.
71. Krivit W. Bone marrow transplantation as treatment for storage diseases: background review and specific application to Gaucher's disease. Jpn J Inborn Errors Metab 1991; 1-13.
72. Schiffmann R, Heyes MP, Aerts JM, Danbrusia JM, Patterson MC, DeGraba R, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrtosidase in patients with type 3 Gaucher disease. Ann Neurol 1997; 42:613-621.
73. Eriskson A, Bembi B, Schiffmann R. Enzyme replacement therapy in Gaucher type III. Bailleres Clinical Hematology 1997; 10:711-723.
74. Ringden O, Groth CG, Winiarski J. Bone marrow transplantation for Gaucher Disease. In: Correction of genetic diseases by transplantation. Ringden O, Hobbs JR, Steward CG (editors). COGENT IV; Middlesex: Westminster Printing Press; 1997. pp. 80-86 Good data is provided on the use of bone marrow transplantation for Gaucher disease.
75. Erikson A, Mannson JE. Enzyme infusion therapy of gaucher disease. In: Correction of genetic diseases by transplantation. Ringden O, Hobbs JR, Steward CG (editors). COGENT IV; Middlesex: Westminster Printing Press; 1997. pp. 87-90.
76. Brady RO. Therapy for the sphingolipidosis. Arch Neurol 1998; 55:1055-1056.
77. Ringden O, Groth CG, Winiarski J. Bone marrow transplantation for Gaucher disease. In: Correction of genetic diseases by transplantation. Ringden O, Hobbs JR, Steward CG (editors). COGENT IV; Middlesex: Westminster Printing Press; 1997. pp. 80-86.
78. Erikson A, Mannson JE. Enzme infusion therapy of Gaucher disease. In: Correction of genetic diseases by transplantation. Ringden O, Hoobs JR, Steward CG (editors). COGENT IV; Middlesex: Westminster Printing Press; 1997. pp 87-90.
79. Kitagawa T. Enzyme therapy for type III Gaucher disease. Jpn Soc Lipid Disord 1998;
80. Platt FM, Neises GR, Reinhensmeier G, Townsend MJ, Perry VH, Prola RL. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 1997; 176: 428-311.
81. Platt FR, Butters TD. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem. Pharmaco. 1998; 56: 421-430.